Factors of the immune microenvironment and the state of the extracellular matrix in vulvar cancer
- Authors: Zlatnik E.Y.1, Ulyanova E.P.1, Nepomnyashchaya E.M.1, Abdullaeva N.M.1, Verenikina .V.1
-
Affiliations:
- National Medical Research Center of Oncology
- Issue: Vol 104, No 2 (2023)
- Pages: 207-215
- Section: Theoretical and clinical medicine
- Submitted: 11.07.2022
- Accepted: 16.02.2023
- Published: 26.03.2023
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/109286
- DOI: https://doi.org/10.17816/KMJ109286
- ID: 109286
Cite item
Abstract
Background. The progression of malignant tumors, including vulvar cancer, largely depends on the state of the extracellular matrix and immune microenvironment of the tumor, the study of which is an urgent problem of oncology to identify the most prognostically significant of them.
Aim. To evaluate the expression of extracellular matrix and local immunity factors, as well as their relationships in vulvar cancer with different prevalence.
Material and methods. A retrospective study on vulvar tumors in 56 patients with stage I (n=20), stage II (n=26) and relapses (n=10) was performed. The expression of markers of the extracellular matrix (matrix metalloproteinases MMP-2 and MMP-9, tissue inhibitor of metalloproteinase-2 TIMP-2) and local immunity (FOXP3, CD68, CD206) was determined by immunohistochemical method. Statistical processing was performed using the Mann–Whitney U-test and multiple correlation analysis with the calculation of paired and partial R coefficients.
Results. The depth of invasion proved to be more informative for detecting multidirectional differences in the expression of MMP-2 and TIMP-2 than the stage. Infiltration by CD68+-macrophages in the stroma increased in parallel with the stage and did not differ at different depths of invasion; infiltration by macrophages M2 (CD206+) increased at stage II compared with stage I (Me 13 and 5, respectively, p=0.03). Differences were noted only in the stroma of tumors, as well as an increase in T-regs (FOXP3) with an increase in the depth of invasion (Me 25 and 8, respectively, p=0.0359). As the prevalence of the tumor developed, the number of correlation relationships between the parameters of local immunity of the parenchyma and tumor stroma increased: 2 statistically significant correlations that do not depend on covariates, 7 that depend on the stage, and 6 that depend on the depth of invasion, were found. Correlations of factors of the immune microenvironment with the extracellular matrix weakened.
Conclusion. The levels of MMP-2, TIMP-2, CD68+, CD206+, FOXP3 reflect the progression of vulvar cancer and can be used to predict the course of the disease; infiltration of tumors by macrophages, T-regs characterizes the stage of the primary tumor rather than recurrence.
Full Text
About the authors
Elena Yu. Zlatnik
National Medical Research Center of Oncology
Author for correspondence.
Email: elena-zlatnik@mail.ru
ORCID iD: 0000-0002-1410-122X
M.D., D. Sci. (Med.), Prof., Chief Researcher, Laboratory of Immunophenotyping of Tumors
Russian Federation, Rostov-on-Don, RussiaElena P. Ulyanova
National Medical Research Center of Oncology
Email: uljanova_elena@lenta.ru
ORCID iD: 0000-0001-5226-0152
Researcher, Laboratory of Tumor Immunophenotyping
Russian Federation, Rostov-on-Don, RussiaEugenia M. Nepomnyashchaya
National Medical Research Center of Oncology
Email: evgeniyamarkovna@mail.ru
ORCID iD: 0000-0003-0521-8837
M.D., D. Sci. (Med.), Prof.
Russian Federation, Rostov-on-Don, RussiaNina M. Abdullaeva
National Medical Research Center of Oncology
Email: kurbanovanina416@gmail.com
ORCID iD: 0000-0002-7364-1963
Junior Researcher, Depart. of Tumors of the Reproductive System
Russian Federation, Rostov-on-Don, RussiaEkaterina V. Verenikina
National Medical Research Center of Oncology
Email: iftrnioi@yandex.ru
ORCID iD: 0000-0002-1084-5176
SPIN-code: 6610-7824
M.D., D. Sci. (Med.), Head of Depart., Depart. of Tumors of the Reproductive System
Russian Federation, Rostov-on-Don, RussiaReferences
- De Smedt L, Palmans S, Andel D, Govaere O, Boeckx B, Smeets D, Galle E, Wouters J, Barras D, Suffiotti M, Dekervel J, Tousseyn T, De Hertogh G, Prenen H, Tejpar S, Lambrechts D, Sagaert X. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br J Cancer. 2017;116(1):58–65. doi: 10.1038/bjc.2016.382.
- Herbster S, Paladino A, de Freitas S, Boccardo E. Alterations in the expression and activity of extracellular matrix components in HPV-associated infections and diseases. Clinics (Sao Paulo). 2018;73(1):e551s. doi: 10.6061/clinics/2018/e551s.
- Kortekaas KE, Santegoets SJ, Abdulrahman Z, van Ham VJ, van der Tol M, Ehsan I, van Doorn HC, Bosse T, van Poelgeest MIE, van der Burg SH. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status. J Immunother Cancer. 2019;7(1):236. doi: 10.1186/s40425-019-0712-z.
- Nerodo GA, Novikova IA, Zlatnik EYu, Nepomnyashchaya EM, Dzhenkova EA, Ivanova VA, Verenikina EV, Uliaanova EP, Tadzhibaeva YuT. Prognostic significance of some immunohistochemical markers in patients with vulvar cancer. Izvestiya vysshikh uchebnykh zavedeniy. Severo-Kavkazskiy region. Seriya: Estestvennye nauki. 2017;(4-2):96–104. (In Russ.) doi: 10.23683/0321-3005-2017-4-2-96-103.
- Kit OI, Nerodo GA, Nepomnyashchaya EM, Novikova IA, Ul’yanova EP, Ivanova VA, Nerodo EA. Sposob prognozirovaniya dlitel’nosti remissii u bol’nykh rakom vul’vy. (Method for remission duration prediction in patients with vulva cancer.) Patent for invention RF No. 2624508. Bulletin No. 19 issued at 04.07.2017. (In Russ.)
- Verenikina EV, Abdulaeva NM, Zlatnik EYu, Ulyanova EP, Bykadorova OV, Lysenko IB, Maksimova NA. Cancer stem cells` markers expression in primary with different stage and depth of invasion and recurrent vulvar carcinoma. Sovremennye problemy nauki i obrazovaniya. 2021;(6):142. (In Russ.)
- Zhang H, Li G, Zhang Z, Wang S, Zhang S. MMP-2 and MMP-9 gene polymorphisms associated with cervical cancer risk. Int J Clin Exp Pathol. 2017;10(12):11760–11765. PMID: 31966538.
- Webb AH, Gao BT, Goldsmith ZK, Irvine AS, Saleh N, Lee RP, Lendermon JB, Bheemreddy R, Zhang Q, Brennan RC, Johnson D, Wilson MW, Morales-Tirado VM. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017;17:434. doi: 10.1186/s12885-017-3418-y.
- Zhou CY, Yao JF, Chen XD. Expression of matrix metalloproteinase-2, -9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix. Ai Zheng. 2002;21(7):735–739.
- Song Z, Wang J, Su Q, Luan M, Chen X, Xu X. The role of MMP-2 and MMP-9 in the metastasis and development of hypopharyngeal carcinoma. Braz J Otorhinolaryngol. 2021;87(5):521–528. doi: 10.1016/j.bjorl.2019.10.009.
- Elkington PT, Green JA, Friedland JS. Analysis of matrix metalloproteinase secretion by macrophages. Methods Mol Biol. 2009;531:253–265. doi: 10.1007/978-1-59745-396-7_16.
- Nishio K, Motozawa K, Omagari D, Gojoubori T, Ikeda T, Asano M, Gionhaku N. Comparison of MMP2 and MMP9 expression levels between primary and metastatic regions of oral squamous cell carcinoma. J Oral Sci. 2016;58(1):59–65. doi: 10.2334/josnusd.58.59.
- Winerdal ME, Krantz D, Hartana CA, Zirakzadeh AA, Linton L, Bergman EA, Rosenblatt R, Vasko J, Alamdari F, Hansson J, Holmström B, Johansson M, Winerdal M, Marits P, Sherif A, Winqvist O. Urinary bladder cancer Tregs suppress MMP2 and potentially regulate invasiveness. Cancer Immunol Res. 2018;6(5):528–538. doi: 10.1158/2326-6066.
- Ansorge N, Dannecker C, Jeschke U, Schmoeckel E, Heidegger HH, Vattai A, Burgmann M, Czogalla B, Mahner S, Fuerst S. Regulatory T cells with additional COX-2 expression are independent negative prognosticators for vulvar cancer patients. Int J Mol Sci. 2022;23(9):4662. doi: 10.3390/ijms23094662.